Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort

EpiCom-group

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.

METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].

RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p <0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93].

CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.

Original languageEnglish
Pages (from-to)747-753
Number of pages7
JournalJournal of Crohn's and Colitis
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Inflammatory Bowel Diseases
Eastern Europe
Crohn Disease
Hospitalization
Western Australia
Ulcerative Colitis
Therapeutics
Biological Therapy
Colectomy
Immunosuppressive Agents
Databases
Phenotype
Incidence

Keywords

  • hospitalization
  • Inflammatory bowel diseases
  • surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6425deb93fe94906811597d19851bcad,
title = "Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort",
abstract = "BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].RESULTS: In CD, 36 [19{\%}] Western Europe/Australian and 6 [9{\%}] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53{\%} vs 45{\%}; p = 0.27]. Surgery was performed in 17 [24{\%}] CD patients in Eastern Europe and 13 [7{\%}] in Western Europe/Australia [p <0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34{\%}] were hospitalized, and 39 [21{\%}] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16{\%} vs 16{\%}; p = 0.93].CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.",
keywords = "hospitalization, Inflammatory bowel diseases, surgery",
author = "EpiCom-group and Z. Vegh and J. Burisch and N. Pedersen and I. Kaimakliotis and D. Duricova and M. Bortlik and Vinding, {K. Kofod} and S. Avnstr{\o}m and J. Olsen and Nielsen, {K. R.} and Katsanos, {K. H.} and Tsianos, {E. V.} and L. Lakatos and D. Schwartz and S. Odes and R. D'Inc{\`a} and M. Beltrami and G. Kiudelis and L. Kupcinskap and A. Jucov and S. Turcan and Barros, {L. F.} and F. Magro and D. Lazar and A. Goldis and {de Castro}, L. and V. Hernandez and O. Niewiadomski and S. Bell and E. Langholz and P. Munkholm and P. Lakatos",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/ecco-jcc/jjv099",
language = "English",
volume = "9",
pages = "747--753",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort

AU - EpiCom-group

AU - Vegh, Z.

AU - Burisch, J.

AU - Pedersen, N.

AU - Kaimakliotis, I.

AU - Duricova, D.

AU - Bortlik, M.

AU - Vinding, K. Kofod

AU - Avnstrøm, S.

AU - Olsen, J.

AU - Nielsen, K. R.

AU - Katsanos, K. H.

AU - Tsianos, E. V.

AU - Lakatos, L.

AU - Schwartz, D.

AU - Odes, S.

AU - D'Incà, R.

AU - Beltrami, M.

AU - Kiudelis, G.

AU - Kupcinskap, L.

AU - Jucov, A.

AU - Turcan, S.

AU - Barros, L. F.

AU - Magro, F.

AU - Lazar, D.

AU - Goldis, A.

AU - de Castro, L.

AU - Hernandez, V.

AU - Niewiadomski, O.

AU - Bell, S.

AU - Langholz, E.

AU - Munkholm, P.

AU - Lakatos, P.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p <0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93].CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.

AB - BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p <0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93].CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.

KW - hospitalization

KW - Inflammatory bowel diseases

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=84973444990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973444990&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjv099

DO - 10.1093/ecco-jcc/jjv099

M3 - Article

C2 - 26055976

AN - SCOPUS:84973444990

VL - 9

SP - 747

EP - 753

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 9

ER -